Výsledky vyhledávání - "Vania Tm Hungria"

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR

Autor: Suzanne Lentzsch, Michele Cavo, Pieter Sonneveld, Alberto Bosi, Tomer M Mark, Andrew Spencer, Hang Quach, Je-Jung Lee, Jon Ukropec, Maria-Victoria Mateos, Ming Qi, Katja Weisel, Meral Beksac, Vania Tm Hungria, Ajay K. Nooka, David Soong, Markus Munder, Hervé Avet-Loiseau, Ivan Spicka

Publikováno v: Journal of Clinical Oncology. 37:8040-8040

8040 Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited tolerability in RRMM pts. We conducted a subgroup an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::340e0a7b5af57bc75ab01e1f0be66b1f
https://doi.org/10.1200/jco.2019.37.15_suppl.8040

Zobrazit plný text záznamu

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid

Autor: Saroj Vadhan-Raj, François Goldwasser, Vania Tm Hungria, R. von Moos, Amy Feng, Charles S. Cleeland, Yi Qian, David H. Henry, Donald L. Patrick, Karen Chung, Lesley Fallowfield, Howard S. Yeh, Silvia Novello

Background Patients with metastatic bone disease are living longer in the metastatic stage due to improvements in cancer therapy, making strategies to prevent the aggravation of bone disease and its complications, such as skeletal-related events (SRE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aa9eb7dfc74c4094bcd76a65336fa8c
http://hdl.handle.net/2318/119643

Zobrazit plný text záznamu

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Publikováno v: Blood. 124:4742-4742

Introduction: Panobinostat (PAN) is a potent pan-deacetylase inhibitor (pan-DACi) that targets key aberrations in multiple myeloma (MM) cell biology, including protein metabolism and epigenetics. In a randomized phase 3 clinical trial in patients (pt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::34251f8cc37fd32a04673e2744fcac21
https://doi.org/10.1182/blood.v124.21.4742.4742

Zobrazit plný text záznamu

Reply to S.M. Sorscher et al

Autor: Saroj Vadhan-Raj, Wolfgang Willenbacher, Roger Dansey, Harm Sleeboom, Jianming Wang, Qi-Zhong Jiang, Vania Tm Hungria, François Goldwasser, Roger von Moos, Howard S. Yeh, Giorgio V. Scagliotti, Vera Hirsh, Luis Costa, Susie Jun, David H. Henry, Jana Prausova, Andrew Spencer

Publikováno v: Journal of Clinical Oncology. 29:2736-2737

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c683aa04a94230f41306251adc88a36c
https://doi.org/10.1200/jco.2011.35.9182

Zobrazit plný text záznamu

Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial

Autor: Susie Jun, Vania Tm Hungria, François Goldwasser, Roger Dansey, G.V. Scagliotti, Howard S. Yeh, Jianming Wang, R. von Moos, David H. Henry, Saroj Vadhan-Raj

Publikováno v: Journal of Clinical Oncology. 28:9042-9042

9042 Background: Bone metastases from solid tumors increase risk for skeletal-related events (SREs, defined as pathologic fractures, spinal cord compression, and radiation or surgery to bone) by stimulating osteoclast-mediated bone resorption. Denosu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e49cb6cc2b1af1b1840520214820fb9
https://doi.org/10.1200/jco.2010.28.15_suppl.9042

Zobrazit plný text záznamu

Results From a Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trial Comparing Denosumab with Zoledronic Acid for the Management of Bone Metastases in Patients with Advanced Solid Tumors or Multiple Myeloma

Autor: Roger Dansey, Jianming Wang, Vera Hirsh, Yeh Howard, Vania Tm Hungria, Saroj Vadhan-Raj, Roger von Moos, Jun Susie, David H. Henry, Andrew Spencer

Publikováno v: Bone. 46:S44

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6e8a9cd9d4ad612c66c846e7cf6b2f0
https://doi.org/10.1016/j.bone.2010.01.098

Zobrazit plný text záznamu

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA

Publikováno v: Web of Science

8005 Background: In a phase 1b trial, a SC formulation of DARA with recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE drug delivery technology, Halozyme, Inc.) had adequate PK, low rates of infusion-related reactions (IRRs) and similar efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40fba21803d8dff757f3accf7976f7ea
https://publons.com/wos-op/publon/28079972/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání